Compare CVS Health Corp (CVS) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Moody's Corporation — how do they compare? CVS Health Corp trades at $104.03 (market cap $135.48B), while Moody's Corporation trades at $493.7 (market cap $86.42B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | MCO | |
|---|---|---|
Market Cap | $135.48B | $86.42B |
Sector | Health | Financials |
52-Week High | $106.18 | $539.61 |
52-Week Low | $58.75 | $412.23 |
Enterprise Value | $202.02B | $92.22B |
Dividend Yield | 2.51% | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
MCO trades at $495.72, up 1.73% today, with strong technical momentum as price hovers near pivot point resistance at $496. The company demonstrates robust fundamentals with 31.69% net margins and consistent earnings beats, while recent AI platform expansions signal growth initiatives. Analyst consensus remains bullish with a $539.40 price target, though valuation multiples appear elevated.
Outlook remains positive given earnings momentum and strategic AI investments, but high P/E of 35.56 presents valuation risk. Key catalysts include Q2 2026 earnings release on July 22, while regulatory scrutiny and debt market sensitivity represent ongoing headwinds for the credit ratings leader.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
